Overview
- The CNIO-led preclinical study reported complete and lasting tumor regression in multiple mouse models and patient-derived xenografts without observed relapse for more than 200 days.
- The regimen targets the KRAS signaling network at three nodes using daraxonrasib (KRAS inhibitor), afatinib (EGFR/HER2 inhibitor), and SD36 (STAT3 degrader).
- Pancreatic ductal adenocarcinoma is driven by KRAS mutations in the vast majority of cases and commonly develops resistance to single-agent therapies, motivating multi-target strategies.
- Study authors stress the findings are preclinical and say the combination is not ready for clinical testing, noting that optimizing dosing and safety for patients will be complex.
- Independent experts caution that mouse successes often do not translate directly to humans, estimating that rigorous trials could take many years before any potential patient benefit is known.